Loading...
•
Jun 30, 2024
IRadimed Q2 2024 Earnings Report
IRadimed's Q2 2024 results were announced, featuring record revenue and increased operating income.
Key Takeaways
IRadimed Corporation reported record revenue of $17.9 million for Q2 2024, an 11.2% increase year-over-year. GAAP diluted EPS was $0.38, and non-GAAP diluted EPS was $0.42. Operating income increased by 13.4% to $5.6 million compared to the same period in 2023. The company declared a quarterly cash dividend of $0.15 per share.
Record revenue of $17.9 million, up 11.2% year-over-year.
GAAP diluted EPS of $0.38 and non-GAAP diluted EPS of $0.42.
Operating income increased 13.4% to $5.6 million year-over-year.
Quarterly cash dividend of $0.15 per share declared.
Forward Guidance
IRADIMED anticipates revenue of $18.0 million to $18.2 million, GAAP diluted earnings per share of $0.34 to $0.37, and non-GAAP diluted earnings per share of $0.38 to $0.41 for Q3 2024. The company reiterates its full-year guidance with revenue expected to be $72.0 million to $74.0 million, GAAP diluted earnings per share of $1.37 to $1.47, and non-GAAP diluted earnings per share of $1.52 to $1.62.
Positive Outlook
- Expects Q3 2024 revenue of $18.0 million to $18.2 million.
- Expects Q3 2024 GAAP diluted earnings per share of $0.34 to $0.37.
- Expects Q3 2024 non-GAAP diluted earnings per share of $0.38 to $0.41.
- Reiterates full-year revenue guidance of $72.0 million to $74.0 million.
- Reiterates full-year GAAP diluted earnings per share guidance of $1.37 to $1.47.
Challenges Ahead
- Full year non-GAAP diluted earnings per share guidance excludes stock-based compensation expense, net of tax expense.
- Anticipates spending approximately $12 million in cash for its new facility development over the next nine to twelve months.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...